Larimar Therapeutics, Inc.

LRMR Healthcare Biotechnology

In the quarter to June 2026, EPS grew 26.8% and free cash flow fell 127.6%, each against the same quarter a year earlier. Insiders bought in the last twelve months.

1.99 0.00 0.00%
Market cap
$206.7M
P/E
0.0×
Fwd P/E
—
Dividend yield
—
F-score
n/a
Altman Z
n/a
Beneish M
n/a
Dividend safety
n/a
Jun '26 Mar '26 Dec '25 Sep '25 Older periods
Current Ratio
4.70 4.29 2.19 4.06

+8 more quarters

Net Debt/EBITDA
4.51 6.44 2.14 3.53
Debt/Equity
0.00 0.00 0.00 0.00
Free Cash Flow per Share
(0.43) (0.50) (0.53) (0.37)
Book value per Share
1.23 1.76 1.07 1.78
Free Cash Flow
(44.16) (44.61) (38.53) (28.78)
Other line items

Show all line items

Columns are period end dates